The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19.
Aysel ToçogluHamad DheirTaner DemirciRumeysa KurtSalih SalihiSelcuk YaylacıGözde Çakırsoy ÇakarHande Toptan ÇakarYasemin GündüzSava S SipahiPublished in: Revista da Associacao Medica Brasileira (1992) (2021)
Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- intensive care unit
- coronavirus disease
- high dose
- low dose
- sars cov
- newly diagnosed
- randomized controlled trial
- systematic review
- ejection fraction
- prognostic factors
- risk factors
- clinical trial
- early onset
- mechanical ventilation
- patient reported outcomes
- drug induced
- combination therapy
- patient reported